
Neuroendocrine tumours: choosing the best treatment
An increasing number of new anti-cancer drugs are made available each year. During the authorisation…
An increasing number of new anti-cancer drugs are made available each year. During the authorisation…
Pheochromocytomas and paragangliomas are rare neuroendocrine tumours with a strong hereditary component. Half the genes…
Data from the ongoing phase Ib/II clinical trial of sulfatinib in patients with advanced neuroendocrine…
A new therapy in development for the treatment of midgut neuroendocrine tumours, a rare type…
More than ten years of published clinical data and personal experience using peptide receptor radionuclide…
Aggressive neuroendocrine cancer is something of a dark horse—a rare, elusive and persevering force linked…
Early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine…
Researchers report the results of a new analysis from a phase III trial of patients…
ANSTO announces that a license has been issued by the Therapeutic Goods Administration to produce…